



Public Health Advisory
10/7/2024

COVID-19 Vaccines for the 2024-2025 Season

SITUATIONAL AWARENESS SUMMARY

Situation: The [U.S. Food and Drug Administration’s \(FDA\) has approved](#) Emergency Use Authorization (EUA) for updated formulations of the Moderna, Pfizer-BioNTech, and Novavax COVID-19 vaccines for the 2024-2025 season.

- The 2023-2024 COVID-19 vaccine formulations have been deauthorized and should no longer be administered.
- The 2024-2025 vaccines have been updated to include components that more closely target currently circulating variants of SARS-CoV-2.
- [Moderna](#) and [Pfizer-BioNTech](#) 2024-2025 formulations include a monovalent component aligned with the Omicron variant KP.2 strain.
- [Novavax](#) 2024-2025 formulation includes a monovalent component aligned with the Omicron variant JN.1 strain.

Recommendations for Providers on COVID-19 Vaccinations

✓ **Ensure Up-to-date Vaccine Supply:**

- **Critical Update: Administering 2023-2024 mRNA COVID-19 vaccines are now considered a vaccine administration error and must be reported to the Vaccine Adverse Event Reporting System (VAERS).**
- **Action Required:** Immediately remove all unused 2023–2024 COVID-19 vaccines from your inventory. Return unused doses to the CDC’s centralized distributor as per the established protocol for handling expired or spoiled vaccines.

✓ **Recommended COVID-19 Vaccines:**

Vaccine	Recommended for
2024-2025 Moderna COVID-19 Vaccine	Everyone ages 6 months and older
2024-2025 Pfizer-BioNTech COVID-19 Vaccine	Everyone ages 6 months and older
2024-2025 Novavax COVID-19 Vaccine	Everyone ages 12 years and older

✓ **Vaccination Considerations:**

- **Universal Recommendation:** Everyone ages 6 months and older should get a 2024-2025 COVID-19 vaccine.
- **Ongoing Protection:** Immunity from vaccination decreases over time, making it essential for individuals to stay up to date with the latest formulations to maintain optimal protection.
- **Additional Considerations:** There are [further considerations](#) for children 6 months to 4 years, people who are moderately to severely immunocompromised, people who recently had COVID-19 or recently received the 2023-2024 vaccine.

Fermin Leguen, MD, MPH
District Health Officer
Southern Nevada Health District

Reference Links

The complete URLs for the shortened links are listed below to copy and paste into your browser.

- U.S. Food and Drug Administration's (FDA) has approved Emergency Use Authorization (EUA) <https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently>
- Moderna <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/moderna-covid-19-vaccine>
- Pfizer-BioNTech <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/pfizer-biontech-covid-19-vaccine>
- Novavax <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted>
- Further considerations <https://www.cdc.gov/covid/vaccines/stay-up-to-date.html>